Supplementary Figure S1. (A) Corneal lymphangiogenesis as detected by lymphatic vessel endothelial hyaluronan receptor (LYVE)-1 immunostaining. (B) Subconjunctival administration of prospero homeobox 1 (Prox1-1) induced dose-dependent inhibition of lymphangiogenesis, with 10 µM as the lowest dose showing the most effective inhibition of lymphangiogenesis (n = 5 per group).
**Supplementary Figure S2.** Phalloidin immunostaining of new vessel wall formation. Prominent new vessel formation was evident in the corneal stroma of scrambled siRNA-treated eyes (A–C), whereas few new vessels were detected in those treated with prospero homeobox 1 (Prox1-1) siRNA (D–F) or bevacizumab (G–I). Scale bars, 100 µm.